All In Biotech

Drug Trial Radar · NCT01774721

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

ARCHER 1050: A RANDOMIZED, OPEN-LABEL, PHASE 3, EFFICACY AND SAFETY STUDY OF DACOMITINIB (PF-00299804) VERSUS GEFITINIB FOR THE FIRST LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SUBJECTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATING MUTATION(S)

Last checked: Nov 20, 2026Latest source record: Nov 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 452 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

452

Actual

Start

May 9, 2013

Primary completion

Jul 29, 2016

Study completion Jan 27, 2022

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 24, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multinational, multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of treatment with dacomitinib (PF-00299804) to treatment with gefitinib in patients with locally advanced or metastatic non-small cell lung cancer, with epidermal growth factor receptor EGFR-activating mutation (s). Analyses of primary objective (Progression Free Survival) will be done as defined in the protocol.

Conditions

  • Non-small Cell Lung Cancer With EGFR-Activating Mutations

Interventions

  • Dacomitinib (PF-00299804)Drug

    Dacomitinib (PF-00299804) 45 mg tablets, continuous oral daily dosing.

  • GefitinibDrug

    Gefitinib 250 mg tablets, continuous oral daily dosing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) ReviewTime frame: Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)

Locations

52 sites in 7 countries. Site status is shown where the registry gives one.

  • Site not named

    Beijing, China

  • Site not named

    Changchun, China

  • Site not named

    Changsha, China

  • Site not named

    Chengdu, China

  • Site not named

    Chongqing, China

  • Site not named

    Fuzhou, China

  • Site not named

    Guangzhou, China

  • Site not named

    Hangzhou, China

  • Site not named

    Hefei, China

  • Site not named

    Nanning, China

  • Site not named

    Shanghai, China

  • Site not named

    Shenyang, China

  • Site not named

    Tianjin, China

  • Site not named

    Wuhan, China

  • Site not named

    Wuxi, China

  • Site not named

    Hong Kong, Hong Kong

  • Site not named

    Shatin, Hong Kong

  • Site not named

    Catania, Italy

  • Site not named

    Lecco, Italy

  • Site not named

    Livorno, Italy

  • Site not named

    Meldola, Italy

  • Site not named

    Milan, Italy

  • Site not named

    Naples, Italy

  • Site not named

    Perugia, Italy

  • Site not named

    Ravenna, Italy

  • Site not named

    Roma, Italy

  • Site not named

    Trento, Italy

  • Site not named

    Viterbo, Italy

  • Site not named

    Hokkaido, Asahikawa, Japan

  • Site not named

    Kashiwa, Chiba, Japan

  • Site not named

    Matsuyama, Ehime, Japan

  • Site not named

    Yokohama, Kanagawa, Japan

  • Site not named

    Tokyo, Koto-ku, Japan

  • Site not named

    Sakai, Osaka, Japan

  • Site not named

    Sayama, Osaka, Japan

  • Site not named

    Sunto-gun, Shizouka, Japan

  • Site not named

    Chuo-Ku, Tokyo, Japan

  • Site not named

    Gdansk, Poland

  • Site not named

    Olsztyn, Poland

  • Site not named

    Poznan, Poland

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.